Literature DB >> 16652348

The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer.

Denise L Stredrick1, Montserrat Garcia-Closas, Marbin A Pineda, Parveen Bhatti, Bruce H Alexander, Michele M Doody, Jolanta Lissowska, Beata Peplonska, Louise A Brinton, Stephen J Chanock, Jeffery P Struewing, Alice J Sigurdson.   

Abstract

Homozygous mutation in the ATM gene causes ataxia telangiectasia and heterozygous mutation carriers may be at increased risk of breast cancer. We studied a total of 22 ATM variants; 18 variants were analyzed in one of two large population-based studies from the U.S. and Poland, and four variants were analyzed in all 2,856 breast cancer cases and 3,344 controls from the two studies. The missense mutation Ser49Cys (c.146C>G, p.S49C), carried by approximately 2% of subjects, was more common in cases than controls in both study populations, combined odds ratio (OR) 1.69 (95% CI, 1.19-2.40; P=0.004). Another missense mutation at approximately 2% frequency, Phe858Leu (c.2572T>C, p.F858L), was associated with a significant increased risk in the U.S. study but not in Poland, and had a combined OR of 1.44 (95% CI, 0.98-2.11; P=0.06). These analyses provide the most convincing evidence thus far that missense mutations in ATM, particularly p.S49C, may be breast cancer susceptibility alleles. Because of their low frequency, even larger sample sizes are required to more firmly establish these associations. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652348      PMCID: PMC1850333          DOI: 10.1002/humu.20323

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  37 in total

1.  Haplotype and linkage disequilibrium architecture for human cancer-associated genes.

Authors:  Penelope E Bonnen; Peggy J Wang; Marek Kimmel; Ranajit Chakraborty; David L Nelson
Journal:  Genome Res       Date:  2002-12       Impact factor: 9.043

2.  Constitutional alterations of the ATM gene in early onset sporadic breast cancer.

Authors:  P Maillet; H Bonnefoi; G Vaudan-Vutskits; B Pajk; T Cufer; W D Foulkes; P O Chappuis; A P Sappino
Journal:  J Med Genet       Date:  2002-10       Impact factor: 6.318

3.  Assessing the probability that a positive report is false: an approach for molecular epidemiology studies.

Authors:  Sholom Wacholder; Stephen Chanock; Montserrat Garcia-Closas; Laure El Ghormli; Nathaniel Rothman
Journal:  J Natl Cancer Inst       Date:  2004-03-17       Impact factor: 13.506

4.  Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer.

Authors:  Shaun P Scott; Regina Bendix; Philip Chen; Raymond Clark; Thilo Dork; Martin F Lavin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

5.  Dominant negative ATM mutations in breast cancer families.

Authors:  Georgia Chenevix-Trench; Amanda B Spurdle; Magtouf Gatei; Helena Kelly; Anna Marsh; Xiaoqing Chen; Karen Donn; Margaret Cummings; Dale Nyholt; Mark A Jenkins; Clare Scott; Gulietta M Pupo; Thilo Dörk; Regina Bendix; Judy Kirk; Katherine Tucker; Margaret R E McCredie; John L Hopper; Joseph Sambrook; Graham J Mann; Kum Kum Khanna
Journal:  J Natl Cancer Inst       Date:  2002-02-06       Impact factor: 13.506

6.  SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes.

Authors:  Bernice R Packer; Meredith Yeager; Brian Staats; Robert Welch; Andrew Crenshaw; Maureen Kiley; Andrew Eckert; Michael Beerman; Edward Miller; Andrew Bergen; Nathaniel Rothman; Robert Strausberg; Stephen J Chanock
Journal:  Nucleic Acids Res       Date:  2004-01-01       Impact factor: 16.971

7.  Human non-synonymous SNPs: server and survey.

Authors:  Vasily Ramensky; Peer Bork; Shamil Sunyaev
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

8.  The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort.

Authors:  Philip Bretsky; Christopher A Haiman; Shlomit Gilad; Joachim Yahalom; Avital Grossman; Shoshana Paglin; David Van Den Berg; Laurence N Kolonel; Rami Skaliter; Brian E Henderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-08       Impact factor: 4.254

9.  Cancer incidence in the US radiologic technologists health study, 1983-1998.

Authors:  Alice J Sigurdson; Michele Morin Doody; R Sowmya Rao; D Michal Freedman; Bruce H Alexander; Michael Hauptmann; Aparna K Mohan; Shinji Yoshinaga; Deirdre A Hill; Robert Tarone; Kiyohiko Mabuchi; Elaine Ron; Martha S Linet
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

10.  Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?

Authors:  Csilla I Szabo; Mieke Schutte; Annegien Broeks; Jeanine J Houwing-Duistermaat; Yvonne R Thorstenson; Francine Durocher; Rogier A Oldenburg; Marijke Wasielewski; Fabrice Odefrey; Deborah Thompson; Arno N Floore; Jaennelle Kraan; Jan G M Klijn; Ans M W van den Ouweland; Teresa M U Wagner; Peter Devilee; Jacques Simard; Laura J van 't Veer; David E Goldgar; Hanne Meijers-Heijboer
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

View more
  28 in total

Review 1.  Single-nucleotide polymorphisms in the p53 signaling pathway.

Authors:  Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

Review 2.  Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer.

Authors:  Sayem Miah; Charles A S Banks; Mark K Adams; Laurence Florens; Kiven E Lukong; Michael P Washburn
Journal:  Mol Biosyst       Date:  2016-12-20

3.  Functional variations in the ATM gene and susceptibility to differentiated thyroid carcinoma.

Authors:  Li Xu; Elaine Cristina Morari; Qingyi Wei; Erich M Sturgis; Laura S Ward
Journal:  J Clin Endocrinol Metab       Date:  2012-03-21       Impact factor: 5.958

Review 4.  Genomic Biomarkers for Breast Cancer Risk.

Authors:  Michael F Walsh; Katherine L Nathanson; Fergus J Couch; Kenneth Offit
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

5.  p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes.

Authors:  Andrea Prodosmo; Andrea De Amicis; Cecilia Nisticò; Mario Gabriele; Giuliana Di Rocco; Laura Monteonofrio; Maria Piane; Enrico Cundari; Luciana Chessa; Silvia Soddu
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

6.  Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists.

Authors:  Alice J Sigurdson; Parveen Bhatti; Shih-Chen Chang; Preetha Rajaraman; Michele M Doody; Laura Bowen; Steven L Simon; Robert M Weinstock; Martha S Linet; Marvin Rosenstein; Marilyn Stovall; Bruce H Alexander; Dale L Preston; Jeffery P Struewing
Journal:  Breast Cancer Res Treat       Date:  2009-02-12       Impact factor: 4.872

7.  Germline mutations and polymorphisms in the origins of cancers in women.

Authors:  Kim M Hirshfield; Timothy R Rebbeck; Arnold J Levine
Journal:  J Oncol       Date:  2010-01-10       Impact factor: 4.375

Review 8.  Cancer driver mutations in protein kinase genes.

Authors:  Ali Torkamani; Gennady Verkhivker; Nicholas J Schork
Journal:  Cancer Lett       Date:  2008-12-10       Impact factor: 8.679

9.  Association of the ATM gene polymorphisms with papillary thyroid cancer.

Authors:  Yulu Gu; Yaqin Yu; Lizhe Ai; Jieping Shi; Xiaoli Liu; Hui Sun; Yawen Liu
Journal:  Endocrine       Date:  2013-08-08       Impact factor: 3.633

10.  Discovering interactions among BRCA1 and other candidate genes associated with sporadic breast cancer.

Authors:  Shaw-Hwa Lo; Herman Chernoff; Lei Cong; Yuejing Ding; Tian Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.